As of 2022, one-third of US adults experience metabolic diseases. Current therapies treat symptoms but do not address disruptions in signaling pathways of the liver that lead to the development of metabolic diseases. It is now recognized that many genes involved in metabolic disease pathways are alternatively spliced. This research aims to identify real alternative splicing events at genes that can serve as therapeutic targets. Alternative splicing is a critical process by which exons within pre-mRNA are either in- cluded or removed to generate diverse mRNAs and proteins. Transcriptomic data from the livers of both male and female mice under several different conditions–fed versus fasted, wildtype, and ɑ7HMZ mice were analyzed for splicing events using an RNA- seq program, DEXSeq. ɑ7HMZ mice express an alternative form of the transcription factor HNF4a, a critical liver and metabolism regulator. Current RNA-seq programs cannot distinguish alternative splicing from other activity occurring at the gene locus, so manual curation is necessary. Using a curation criterion, I manually analyzed 177 genes identified by the program for alternative splicing events. My analysis identified splicing events at mitochondrial genes usually expressed during fasting conditions and genes whose loss-of-function is implicated in obesity, hyperglycemia, and hypertension. Future research will analyze the mechanistic roles of these mitochondrial genes in various met- abolic disease models.